loan

subject: Menarini: Pharmavitae Profile - Market Research Reports On Aarkstore Enterprise [print this page]

Introduction
Introduction

This analysis examines the historical and forecast performance for Menarini in the prescription pharma sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

*Benchmark Menarini's performance against key rivals in the prescription pharmaceutical sector

*Discover how the company's business model continues to drive sales growth across the established and emerging European markets

*Assess Menarini's position in the hypertension market and the various challenges that its broad antihypertensive portfolio could face

Table of Contents :

"ABOUT HEALTHCARE 2

About the PharmaVitae team 2

Chapter 1 About this profile 3

PharmaVitae Explorer database 3

Chapter structure 3

Executive summary 3

Quarterly update 3

Company introduction 3

Company sales 4

Company financials 4

Key products 4

Data sourcing 4

Sales data 4

Analyst consensus 4

Chapter 2 Executive summary 5

Key findings 5

Prescription pharmaceutical sales and growth rate performance, 2003-15 6

Menarini: PharmaVitae forecasts at a glance 7

Strategic insight 8

Robust strategic focus helps drive growth 8

Antihypertensive proposition set to drive an otherwise diverse therapeutic focus 11

SWOT analysis 13

Table of Contents 13

Table of figures 15

Chapter 3 Quarterly news update 16

Latest prescription pharma product news 16

Q1 2010 16

Q4 2009 16

Q3 2009 16

Latest corporate news 17

Q1 2010 17

Q4 2009 17

Q3 2009 17

Chapter 4 Company introduction 18

Key findings 18

Background 19

Key corporate developments 19

M&A history 19

Chapter 5 Company sales 21

Key findings 21

Prescription pharmaceutical sales and growth rate analysis, 2003-15 22

Product analysis 23

Product analysis, 2003-09 24

Product analysis, 2009-15 26

Therapy area analysis 29

Geographic analysis 31

Launch/core/expiry analysis 33

Explanation of launch/core/expiry analysis 33

Launch analysis, 2009-15 34

Core analysis, 2009-15 35

Expiry analysis, 2009-15 36

Launch/core/expiry configuration, 2009-15 37

Molecule type analysis 38

Externalization analysis 39

Chapter 6 Appendix 41

References 41

Abbreviations 41

Exchange rates 43

About 44

About Healthcare 44

consulting 44

Disclaimer 46

List of Tables

Table 1: Menarini - PharmaVitae forecasts at a glance 7

Table 2: Menarini's antihypertensive portfolio 11

Table 3: Menarini product portfolio overview ($m), 2003-09 24

Table 4: Menarini product portfolio overview ($m), 2009-15 26

Table 5: Menarini prescription pharmaceutical sales by therapy area ($m), 2009-15 30

Table 6: Menarini prescription pharmaceutical sales by geographic region ($m), 2009-15 32

Table 7: Menarini launch portfolio overview ($m), 2009-15 34

Table 8: Menarini core portfolio overview ($m), 2009-15 35

Table 9: Menarini expiry portfolio overview ($m), 2009-15 36

Table 10: Menarini prescription pharmaceutical sales by source ($m), 2009-15 40

Table 11: Exchange rates, 2010 43

List of Figures

Figure 1: The PharmaVitae Explorer 3

Figure 2: Menarini prescription pharmaceutical performance, sales ($m) and growth rate (%), 2003-15 6

Figure 3: Menarini's geographical focus, 2003-09, sales ($m) 8

Figure 4: Menarini's externalization focus, 2003-09, sales ($m) 9

Figure 5: Top ten companies in Italy by sales ($m), 2009 10

Figure 6: Antihypertensive product sales ($m), 2003-15 12

Figure 7: Menarini SWOT analysis 13

Figure 8: Menarini prescription pharmaceutical performance, sales ($m) and growth rate (%), 2003-15 22

Figure 9: Menarini Key product sales ($m), 2003-15 23

Figure 10: Menarini key sales growth drivers and resistors ($m), 2003-09 25

Figure 11: Menarini key sales growth drivers and resistors ($m), 2009-15 28

Figure 12: Menarini prescription pharmaceutical sales by therapy area ($m), 2003-15 29

Figure 13: Menarini prescription pharmaceutical sales by geographic region ($m), 2003-15 31

Figure 14: Menarini launch/core/expiry configuration ($m), 2009-15 37

Figure 15: Menarini prescription pharmaceutical sales by molecule type ($m), 2003-15 38

Figure 16: Menarini prescription pharmaceutical sales by source ($m), 2003-15 39

For more information please visit :

http://www.aarkstore.com/reports/Menarini-PharmaVitae-Profile-16884.html

by: Aarkstore Enterprise

welcome to loan (http://www.yloan.com/)